Interleukin-6: an osteotropic factor influencing bone formation?
N Franchimont, S Wertz, M Malaise - Bone, 2005 - Elsevier
Interleukin (IL)-6 has long been considered as an osteoresorptive factor. However, recent
data indicate that IL-6 could influence bone formation in conditions of increased bone …
data indicate that IL-6 could influence bone formation in conditions of increased bone …
The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension
…, A Wang, MN Bradley, N Franchimont… - The Journal of …, 2013 - academic.oup.com
Context: The Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months
(FREEDOM) extension is evaluating the long-term efficacy and safety of denosumab for up …
(FREEDOM) extension is evaluating the long-term efficacy and safety of denosumab for up …
Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk
…, J Farrerons, A Wang, N Franchimont… - The Journal of …, 2011 - academic.oup.com
Context: The FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis
every 6 Months) trial showed denosumab significantly reduced the risk of fractures in …
every 6 Months) trial showed denosumab significantly reduced the risk of fractures in …
[HTML][HTML] Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus
…, C Barbey, C Musselli, N Franchimont - … England Journal of …, 2022 - Mass Medical Soc
Background Blood dendritic cell antigen 2 (BDCA2) is a receptor that is exclusively
expressed on plasmacytoid dendritic cells, which are implicated in the pathogenesis of …
expressed on plasmacytoid dendritic cells, which are implicated in the pathogenesis of …
[HTML][HTML] Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus
…, C Musselli, C Barbey, N Franchimont - … England Journal of …, 2022 - Mass Medical Soc
Background Antibody-binding of blood dendritic cell antigen 2 (BDCA2), which is expressed
exclusively on plasmacytoid dendritic cells, suppresses the production of type I interferon …
exclusively on plasmacytoid dendritic cells, suppresses the production of type I interferon …
Increase in cytokine production (IL-1β, IL-6, TNF-α but not IFN-γ, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis
…, D De Groote, PF Zangerlé, J Collette, N Franchimont… - Maturitas, 1997 - Elsevier
Postmenopausal osteoporosis is a progressive disorder characterized by a decreased bone
mass and increased susceptibility to fractures. Several investigations have suggested that …
mass and increased susceptibility to fractures. Several investigations have suggested that …
Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment
C Ribbens, MM y Porras, N Franchimont… - Annals of the …, 2002 - ard.bmj.com
Objective: To determine matrix metalloproteinase-3 (MMP-3) serum levels in patients with
rheumatic diseases and to study the relation between MMP-3 and C reactive protein (CRP) …
rheumatic diseases and to study the relation between MMP-3 and C reactive protein (CRP) …
[HTML][HTML] Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus
…, P Gulati, D Rabah, N Franchimont - The Journal of …, 2019 - Am Soc Clin Investig
BACKGROUND. Plasmacytoid DCs (pDC) produce large amounts of type I IFN (IFN-I),
cytokines convincingly linked to systemic lupus erythematosus (SLE) pathogenesis. BIIB059 …
cytokines convincingly linked to systemic lupus erythematosus (SLE) pathogenesis. BIIB059 …
RANKL inhibition with denosumab does not influence 3‐year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal …
…, AM Cheung, N Franchimont… - Journal of Bone and …, 2014 - academic.oup.com
Atherosclerosis and osteoporosis are chronic diseases that progress with age, and studies
suggest aortic calcification, an indicator of atherosclerosis, is inversely associated with bone …
suggest aortic calcification, an indicator of atherosclerosis, is inversely associated with bone …
Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double …
…, JL Browning, N Franchimont… - Arthritis & …, 2018 - Wiley Online Library
Objective To evaluate the clinical efficacy and safety of baminercept, a lymphotoxin β
receptor IgG fusion protein (LT βR‐Ig), for the treatment of primary Sjögren's syndrome (SS) …
receptor IgG fusion protein (LT βR‐Ig), for the treatment of primary Sjögren's syndrome (SS) …